Document is current
Any future updates will be listed below
-
Authors
Udovica, Simon
Ferner, Muna
Marhold, Maximilian
Strasser-Weippl, Kathrin
Bartsch, Rupert https://orcid.org/0000-0002-4384-6917
-
Funding
Funding for this research was provided by:
Medical University of Vienna
- License Information
-
More Information
Article History
Received: 21 March 2025
Accepted: 23 March 2025
First Online: 14 April 2025
Conflict of interest
: S. Udovica has received honoraria from Johnson & Johnson, Amgen, Oncopeptides, Novartis, Servier, Eli-Lilly, and MedMedia and travel support from AbbVie, AOP-Orphan, Beigene, GlaxoSmithKline, Janssen, Eli-Lilly, Pfizer, Roche, Servier, and Stemline. M. Ferner has received honoraria from MSD and travel support from Roche, Pfizer, Daiichi Sankyo, and Novartis. M. Marhold has received honoraria from Roche, Eli Lilly, Novartis, Astra Zeneca, Daiichi Sankyo, Pfizer, MSD, Gilead, and Medmedia and travel support from Amgen, Gilead, Roche, Novartis, Pierre Fabre, Daiichi Sankyo, and Eisai. K. Strasser-Weippl has received honoraria from Roche, Pfizer, Novartis, Lilly, Daiichi Sankyo, Myriad, Seagen, MSD, and Astra Zeneca and travel support from Roche, Pfizer, and MSD. R. Bartsch has received honoraria from Amgen, Astra-Zeneca, BMS, Daichi, Eisai, Eli-Lilly, Gilead, Gruenenthal, MSD, MedMedia, Novartis, Pfizer, Pierre-Fabre, Roche, Seagen, and Stemline, research support from Daiichi, and travel support from Astra-Zeneca, Daiichi, Ely-Lilly, MSD, and Novartis.
